The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

Lockheed Martin lays off 64 Mass. clean energy workers Lockheed Martin lays off 64 Mass. clean energy workers © 2025 American ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

Microsoft launches Discovery platform that uses agentic AI to compress years of scientific research into days, transforming R&D across pharmaceuticals, materials science, and semiconductor industries.

The 25,000-square-foot center is opening with a staff of 35, but that number is expected to double over the next two years.

The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr.

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...